To develop immunotherapies for cancer, infectious diseases, autoimmune diseases and other disorders, a need exists for high-dimensional profiling to identify and better understand the role of antigen-specific T cells, the key effectors in many diseases. immunoScape’s TargetScape® assay can screen and identify antigen-specific CD8 T cells by their recognition of several hundred candidate antigens simultaneously, as well as deeply characterizing their cellular phenotype.
Read our white paper to find out how TargetScape® technology can help lead to lower candidate attrition rates during clinical development, mitigate clinical trial failure risk, support overall drug development strategies and replenish your drug pipeline with new targets and improved drug candidates.